跳转至内容
Merck

GF55621795

rod, 200mm, diameter 50mm, as drawn, 98+%

别名:

登录查看公司和协议定价


About This Item

线性分子式:
Fe
CAS号:
分子量:
55.85
MDL號碼:
分類程式碼代碼:
12141721
PubChem物質ID:
NACRES:
NA.23

化驗

98%

形狀

rod

製造商/商標名

Goodfellow 556-217-95

電阻係數

9.71 μΩ-cm

長度 × 直徑

200 mm × 50 mm

bp

2750 °C (lit.)

mp

1535 °C (lit.)

密度

7.86 g/mL at 25 °C (lit.)

SMILES 字串

[Fe]

InChI

1S/Fe

InChI 密鑰

XEEYBQQBJWHFJM-UHFFFAOYSA-N

一般說明

For updated SDS information please visit www.goodfellow.com.

法律資訊

Product of Goodfellow

从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

抱歉,我们目前尚未线上提供该产品的COA。

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Catherine F M Bowden et al.
Biochemistry, 53(14), 2286-2294 (2014-03-22)
The Isd (iron-regulated surface determinant) system is a multiprotein transporter that allows bacterium Staphylococcus aureus to take up iron from hemoglobin (Hb) during human infection. In this system, IsdB is a cell wall-anchored surface protein that contains two near iron
Antonino Missineo et al.
Infection and immunity, 82(6), 2448-2459 (2014-04-02)
Staphylococcus lugdunensis is a coagulase-negative staphylococcus that is a commensal of humans and an opportunistic pathogen. It can cause a spectrum of infections, including those that are associated with the ability to form biofilm, such as occurs with endocarditis or
Florence Lima et al.
Environmental and molecular mutagenesis, 55(3), 266-277 (2014-04-12)
DNA methylation is an epigenetic mechanism that drives phenotype and that can be altered by environmental exposures including radiation. The majority of human radiation exposures occur in a relatively low dose range; however, the biological response to low dose radiation
Maria Wilhelm et al.
Clinical nephrology, 81(4), 251-258 (2014-03-25)
Hyperphosphatemia in advanced chronic kidney disease (CKD) necessitates the use of phosphate binders. This in vitro study assessed phosphate binding and Fe release properties of the novel iron-based phosphate binder PA21. Phosphate adsorption and Fe release were assessed under conditions
S J Ford et al.
Annals of the Royal College of Surgeons of England, 96(4), 275-278 (2014-05-02)
The incidence of oesophageal adenocarcinoma (OAC) is rising dramatically and overall survival remains extremely poor. Iron has been shown to potentiate tumourigenesis in OAC, and iron chelation therapy demonstrates promise in vivo as an adjunct to neoadjuvant and palliative chemotherapy.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门